Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism

Chinese Journal of Traumatology - English Edition

Volumn 11, Issue 6, 2008, Pages 352-358

  Qin, Chuan ^a   Xiao, Ying Bin ^a   Zhong, Qian Jin ^a   Chen, Lin ^a   Wang, Xue Feng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Erythropoietin; Myocytes, cardiac; Tumor necrosis factor alpha

Indexed keywords

ERYTHROPOIETIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRROLIDINE DITHIOCARBAMATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HEART MUSCLE CELL; NEWBORN; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REOXYGENATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 63049119016     PISSN: 10081275     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1008-1275(08)60071-1     Document Type: Article

References (24)

1. Schreiber E, Mattias P, Muller MM, et al. Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells. Nucleic Acids Res 1989;17(15): 6419.
2. Beguin Y. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer. Drug Saf 1998; 19(4): 269-282.
3. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133(11): 845-854.
4. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischemic acute renal injury. Nephrol Dial Transplant 2004;19(2): 348-355.
5. Sola A, Wen TC, Hamrick SE, et al. Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr Res 2005; 57(5 Pt 2): 110R-117R.
6. Sekiguchi Y, Kikuchi S, Myers RR. Erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine 2003; 28(23): 2577-2584.
7. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin nd VEGF exhibit equel angiogenic potential. Microvascu Res 2002; 64(2):326-333.
8. Akisu M, Kullahcioglu Girgin F, et al. The role of recombinant human erythropoietin in lipid peroxidation and platelet activating factor generation in a rat model of necrotizing enterocolitis. Eur J Pediatr Surg 2001; 11(3): 167-172.
9. Buemi M, Vaccaro M, Sturiale A, et al. Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischemic flaps. Acta Derm Venereol 2002;82 (6): 411-417.
10. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998;52(3): 235-249.
11. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003; 308(4): 990-994.
12. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100(8): 4802-4806.
13. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112(7): 999-1007.
14. Hirata A, Minanino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006; 48(1):176-84.
15. Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101(1): 31-39.
16. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther 2005; 19(5): 333-336.
17. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005; 100(5): 397-403.
18. Hirata A, Minamino T, Asanuma H. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 2005; 19(1): 33-40.
19. Xu B, Dong GH, Liu H, et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock protein 70 and attenuation of nuclear factor-kappa B. Ann Clin Lab Sci 2005; 35(2): 161-168.
20. Rafiee, P, Shi Y, Su J, et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005; 100(3): 187-197.
21. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97(19):10526-10531.
22. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198(6):971-975.
23. Mitsuma W, Ito M, Kodama M, et al. Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 2006; 344(3): 987-994.
24. Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 2006; 78(19): 2255-2264.